Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.08 EUR
Change Today +0.079 / 1.97%
Volume 5.3K
VSC On Other Exchanges
As of 3:35 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - €7.75
52 Week Low
03/10/15 - €3.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune diseases includes Vidofludimus, an oral small-molecule drug candidate, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of hepatocellular carcinoma, Hodgkin’s lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that has completed Phase I clinical trial for the treatment of hematological tumors; and 4SC-205, an anti-cancer compound, which has completed Phase I clinical trial for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

58 Employees
Last Reported Date: 05/7/15
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €273.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €209.0K
Compensation as of Fiscal Year 2014.

4sc ag (VSC) Key Developments

4SC Ag Strengthens Patent Protection for Lead Cancer Compound Resminostat

4SC AG announced that the company has managed to further strengthen its patent portfolio for its lead clinical anti-cancer programme resminostat. For the epigenetic agent resminostat, an HADC inhibitor targeting in particular HDAC 1, 2, 3 and 6, the U.S. Patent Office has granted the patent for the medical use in cancer indications. The patent relates to the so-called method of treatment claims, and covers medical application of resminostat in mono- and/or combination therapy for cancer indications. In addition, the Canadian patent authority has granted the composition of matter patent for resminostat. Thus resminostat has now composition of matter protection in all major markets including the US, Europe, Japan, China, South Korea, Russia, India, and now Canada. The granting of the two patents constitutes an additional protection against potential competitors and thus further strengthens the protection of 4SC's intellectual property assets, including the composition of matter, mesylate salt and manufacturing patents of resminostat, for which up to date patents have been granted in 58 countries, including the major markets.

4SC AG Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015

4SC AG Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015. Venue: InterContinental Vienna, Vienna, Austria. Presentation Date & Speakers: May-19-2015. May-20-2015, Enno Spillner, Chairman of Management Board, Chief Executive Officer and Chief Financial Officer.

4SC AG Reports Consolidated Financial Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

4SC AG reported consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company’s consolidated revenue was EUR 1.99 million against EUR 1.44 million a year ago. The increase in revenue was mainly due to allocations to Yakult Honsha of costs to produce the resminostat compound. The company's result from operating activities (EBIT) improved by 37% to negative EUR 1.33 million in the first quarter of 2015, primarily on the back of higher revenue. The company reported negative EBIT of 2.12 million in the year 2014. The loss for the period decreased by 27% to EUR 1.54 million against EUR 2.12 million reported in the year 2014. Earnings per share improved to negative EUR 0.03 against negative EUR 0.04 a year ago. Cash from operations amounted to EUR 0.70 million in the reporting period against EUR 0.71 million a year ago. For 2015, the Management Board anticipates a slight decrease in research and development costs and a further reduction in the consolidated net loss from operations as against 2014 as a result of a renewed drop in operating expenses and a rise in the contributions to earnings at the same time. This is, however, contingent on the company's research and development programmes and partnerships continuing to exist and running according to plan and no new clinical studies being started. The company expects to continue posting annual net losses in the short to medium term. For 2015, the Management Board expects the company’s research subsidiary to generate a positive cash flow from operations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €4.08 EUR +0.079

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 84.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at